BRCA1 and neoplasm: In the 2000s, a new class of anticancer drugs specifically targeting a tumor cell population emerged: the poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) that target cells with deficient BRCA1 or BRCA2 proteins [3].